Table 1.
Demographic and virological-immunological features of non-transferred and transferred patients in the Madrid cohort at the end of December 2017.
| Demographic characteristics | Non-transferreda (N = 106) | Transferredb (N = 184) | P value |
|---|---|---|---|
| Female, No. (%) | 61 (57.5) | 106 (57.6) | 1.0000 |
| Route of infection, No. (%) | |||
| Perinatally | 93 (87.7) | 173 (94) | 0.0766 |
| Transfusion | 2 (1.9) | 6 (3.3) | 0.7148 |
| Sexual | 2 (1.9) | 3 (1.6) | 1.0000 |
| Unknown | 9 (8.5) | 2 (1.1) | 0.0024 |
| Age, years, mean [SD], No. (%) | 15.6 [5.7] | 27 [4.2] | < 0.0001 |
| 0 to < 6 | 7 (6.6) | 0 | 0.0008 |
| 6 to < 12 | 22 (20.8) | 0 | < 0.0001 |
| 12 to < 18 | 40 (37.7) | 3 (1.6) | < 0.0001 |
| 18 to < 24 | 31 (29.2) | 44 (23.9) | 0.3187 |
| 24 to ≤ 30 | 6 (5.7) | 93 (50.6) | < 0.0001 |
| > 30 | 0 | 44 (23.9) | < 0.0001 |
| Period of HIV diagnosis, No. (%) | |||
| 1985–1989 | 0 | 30 (16.3) | < 0.0001 |
| 1990–1994 | 4 (3.8) | 88 (47.8) | < 0.0001 |
| 1995–1999 | 23 (21.7) | 49 (26.6) | 0.3491 |
| 2000–2004 | 28 (26.4) | 12 (6.5) | < 0.0001 |
| 2005–2009 | 20 (18.9) | 1 (0.6) | < 0.0001 |
| 2010–2014 | 20 (18.9) | 3 (1.6) | < 0.0001 |
| 2015–2016 | 10 (9.4) | 1 (0.6) | < 0.0001 |
| Unknown | 1 (0.9) | 0 | 0.3655 |
| Age at diagnosis, years, median [IQR], No. (%) | 0.6 [0.2–4.6] | 1.3 [0.4–4.6] | 0.0742 |
| 0 to < 6 | 86 (81.2) | 149 (81.0) | 1.0000 |
| 6 to < 12 | 14 (13.2) | 27 (14.7) | 0.8614 |
| 12 to ≤ 18 | 5 (4.7) | 8 (4.3) | 1.0000 |
| Unknown | 1 (0.9) | 0 | 0.3655 |
| Calendar year of transfer, No. (%) | |||
| 1997–1999 | – | 4 (2.2) | |
| 2000–2002 | – | 9 (4.9) | |
| 2003–2005 | – | 21 (11.4) | |
| 2006–2008 | – | 29 (15.8) | |
| 2009–2011 | – | 47 (25.5) | |
| 2012–2014 | – | 42 (22.8) | |
| 2015–2017 | – | 30 (16.3) | |
| Unknown | – | 2 (1.1) | |
| Age at transfer, years, median [IQR] | – | 18.7 [17.6–20.8] | |
| Origin of birthc, No. (%) | |||
| Spain (West Europe) | 73 (68.9) | 171 (92.9) | < 0.0001 |
| Portugal (West Europe) | 0 | 1 (0.5) | 1.0000 |
| East Europe | 0 | 1 (0.5) | 1.0000 |
| North Africa | 2 (1.9) | 2 (1.1) | 0.6249 |
| Sub-Saharan Africa | 19 (17.9) | 2 (1.1) | < 0.0001 |
| South and Central America | 10 (9.4) | 7 (3.8) | < 0.0001 |
| Asia | 2 (1.9) | 0 | 0.1328 |
| Virological featuresd No. (%) | Non-transferred N = 75 (70.7) |
Transferred N = 133 (72.3) |
P value |
|---|---|---|---|
| Viral load, median [IQR], No. (%) | 35 [20–37] | 37 [20–71] | 0.0441 |
| ≤ 20 | 28 (37.3) | 43 (32.3) | 0.5427 |
| 21–50 | 25 (33.4) | 44 (33.1) | 1.0000 |
| 51–200 | 4 (5.3) | 18 (13.5) | 0.0983 |
| 201–500 | 1 (1.3) | 5 (3.7) | 0.4220 |
| 501–1,000 | 3 (4.0) | 2 (1.5) | 0.3536 |
| 1,001–10,000 | 3 (4.0) | 9 (6.8) | 0.5429 |
| > 10,000 | 3 (4.0) | 11 (8.3) | 0.3876 |
| Unknown | 8 (10.7) | 1 (0.8) | 0.0014 |
| CD4 percentage, mean [SD], No. (%) | 33.3% [9.2] | 31.6% [11.4] | 0.2715 |
| < 25% | 11 (14.7) | 35 (26.3) | 0.0571 |
| 25–50% | 55 (73.3) | 90 (67.7) | 0.4346 |
| > 50% | 1 (1.3) | 7 (5.3) | 0.2631 |
| Unknown | 8 (10.7) | 1 (0.8) | 0.2715 |
| CD4 cells/mm3, median [IQR], No. (%) | 781 [561–962] | 725 [498–901] | 0.279 |
| ≤ 200 | 2 (2.6) | 7 (5.3) | 0.4934 |
| 201–350 | 4 (5.3) | 8 (6.0) | 1.0000 |
| 351–500 | 8 (10.7) | 19 (14.3) | 0.5244 |
| 501–1,000 | 39 (52.0) | 74 (55.7) | 0.6646 |
| 1,001–1,500 | 11 (14.7) | 22 (16.5) | 0.8440 |
| > 1,500 | 3 (4.0) | 2 (1.5) | 0.3536 |
| Unknown | 8 (10.7) | 1 (0.8) | 0.0014 |
| Nadir CD4 percentage, median [IQR], No. (%) | 15% [11–22.7] | 11% [3–16.7] | 0.0001 |
| < 15% | 33 (44.0) | 88 (66.2) | 0.0022 |
| 15–24% | 22 (29.3) | 36 (27.0) | 0.7492 |
| ≥ 25% | 12 (16.0) | 8 (6.0) | 0.0265 |
| Unknown | 8 (10.7) | 1 (0.8) | 0.0014 |
| Nadir CD4 (cells/mm3), median [IQR], No. (%) | 379 [206–500] | 187 [41.2–345.5] | < 0.0001 |
| < 200 | 15 (20.0) | 67 (50.4) | < 0.0001 |
| 200–499 | 35 (46.6) | 57 (42.8) | 0.6632 |
| ≥ 500 | 17 (22.7) | 8 (6.0) | 0.0007 |
| Unknown | 8 (10.7) | 1 (0.8) | 0.0014 |
| CD8 percentage, median [IQR], No. (%) | 36% [28–42] | 39.6% [34–53] | 0.0004 |
| < 25% | 11 (14.6) | 4 (3.0) | 0.0036 |
| 25–50% | 48 (64.0) | 92 (69.2) | 0.4466 |
| > 50% | 8 (10.7) | 36 (27.0) | 0.0049 |
| Unknown | 8 (10.7) | 1 (0.8) | 0.0014 |
| CD8 cells/mm3, median [IQR], No. (%) | 795 [552–1077] | 873 [701–1210] | 0.0232 |
| ≤ 200 | 1 (1.3) | 1 (0.8) | 1.0000 |
| 201–350 | 3 (4.0) | 3 (2.2) | 0.6694 |
| 351–500 | 7 (9.3) | 7 (5.2) | 0.2651 |
| 501–1,000 | 37 (49.4) | 69 (51.9) | 0.7735 |
| 1,001–1,500 | 16 (21.3) | 37 (27.8) | 0.3251 |
| > 1,500 | 3 (4.0) | 15 (11.3) | 0.1208 |
| Unknown | 8 (10.7) | 1 (0.8) | 0.0014 |
| CD4/CD8 ratio [IQR], No. (%) | 0.9 [0.6–2.3] | 0.8 [0.4–1.2] | 0.0205 |
| < 1 | 34 (45.3) | 82 (61.6) | 0.0291 |
| ≥ 1 | 33 (44.0) | 50 (37.6) | 0.0849 |
| Unknown | 8 (10.7) | 1 (0.8) | 0.0014 |
aPatients from Madrid Cohort of HIV-1 infected children and adolescents under follow-up in pediatric units.
bTransferred from pediatric to adult units.
cBirth origin of patients by country: Portugal (n = 1), Romania (n = 1), Morocco (n = 4), Cameroon (n = 1), Equatorial Guinea (n = 15), Mozambique (n = 1), Nigeria (n = 4), Argentina (n = 1), Bolivia (n = 2), Colombia (n = 2), Ecuador (n = 4), Guatemala (n = 1), Haiti (n = 1), Honduras (n = 3), Mexico (n = 1), Peru (n = 1), Dominican Republic (n = 1), China (n = 1), and India (n = 1).
dVirological features in patients with resistance information. Viral Load: HIV-1 RNA-copies/ml. In bold, significant p values (< 0.05).